IDBS Joins SAFE-BioPharma Association’s Vendor Partner Program
News May 11, 2006
IDBS has announced that, as a continuing commitment to quality and industry standards, they have joined the SAFE-BioPharma Association Vendor Partner Program.
SAFE created and manages the SAFE™ digital identity and signature standard used in the pharmaceutical industry.
IDBS will adopt the standard as part of the E-WorkBook suite, including the Electronic Study Management solution (ESM), BioBook™. IDBS are the first ISV and Electronic Lab Notebook (ELN) vendor to join SAFE.
"We are continuing to support the industry standards approach to our products with this commitment," said Neil Kipling, Chairman and CEO of IDBS Ltd.
"The integration of the SAFE standard within the E-WorkBook suite will represent another reason why our solution is industry leading."
"We are pleased to welcome IDBS to the SAFE Vendor Partner Program," said Mollie Shields-Uehling, president and CEO, SAFE-BioPharma Association.
"As part of the expanding SAFE community, IDBS will help scientists and others in the life sciences capture, protect and exchange intellectual property information."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019